Last €96.03 EUR
Change Today +0.41 / 0.43%
Volume 18.5K
BIM On Other Exchanges
Symbol
Exchange
BIM is not on other exchanges.
As of 11:35 AM 03/4/15 All times are local (Market data is delayed by at least 15 minutes).

biomerieux (BIM) Snapshot

Open
€95.60
Previous Close
€95.62
Day High
€96.27
Day Low
€95.10
52 Week High
02/5/15 - €98.89
52 Week Low
03/20/14 - €74.60
Market Cap
3.8B
Average Volume 10 Days
20.4K
EPS TTM
€3.46
Shares Outstanding
39.5M
EX-Date
06/3/14
P/E TM
27.8x
Dividend
€1.00
Dividend Yield
1.04%
Current Stock Chart for BIOMERIEUX (BIM)

Related News

No related news articles were found.

biomerieux (BIM) Related Businessweek News

No Related Businessweek News Found

biomerieux (BIM) Details

bioMérieux SA designs, develops, manufactures, and markets in vitro diagnostic systems for clinical and industrial applications. The company’s diagnostic systems consist of reagents and consumables used to conduct biological tests, for use in performing screening, diagnostic assistance, prognosis, and treatment monitoring; instruments, platforms, or autoanalyzers used for automated testing at high or low throughputs; software to process analyses and systems to interpret the biological test results; and related services, such as the installation and maintenance of instruments, user training, or the audit of laboratory workflows. It offers diagnostic systems for clinical applications, including the diagnosis of infectious diseases, comprising HIV, tuberculosis, and respiratory diseases, as well as cardiovascular diseases and targeted cancers based on the analysis of biological samples, such as blood, saliva, and urine; and for industrial applications, including the analysis of microbiological manufacturing, such as food, pharmaceuticals, and cosmetics. The company markets and sells its products through a network of distributors to private-sector analysis laboratories, hospital laboratories, blood banks, and physician office laboratories; food, pharmaceutical, and cosmetics industries; and independent quality-control laboratories. It has operations in Europe, the Middle East, Africa, North America, Asia-Pacific, and Latin America. The company was formerly known as B-D Mérieux and changed its name to bioMérieux SA. The company was founded in 1963 and is headquartered in Marcy l’Etoile, France. bioMérieux SA is a subsidiary of Institut Mérieux.

8,535 Employees
Last Reported Date: 09/5/14
Founded in 1963

biomerieux (BIM) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: €544.9K
Compensation as of Fiscal Year 2013.

biomerieux (BIM) Key Developments

bioMerieux and Astute Medical, Inc. Signs Agreement to Develop Test for Assessment of AKI

bioMerieux and Astute Medical, Inc. have signed a global, semi-exclusive agreement to develop a test for the early risk assessment of acute kidney injury, or AKI. This innovative test, known as the NephroCheck Test, detects the presence of two biomarkers: TIMP-2 (Tissue Inhibitor Metalloproteinases-2) and IGFBP-7 (Insulin-like Growth Factor-Binding Protein-7). Through this worldwide agreement, Astute Medical grants bioMerieux a license to develop, produce and market the NephroCheck Test for use on its immunoassay system range VIDAS, miniVIDAS and VIDAS 3. Deployment of the NephroCheck Test for the VIDAS platform will benefit from the VIDAS installed base of about 29,000 systems and from complementary large product offering dedicated to diagnosis of severe bacterial infections, in particular with VIDAS B.R.A.H.M.S. PCT. With this new assay, bioMerieux will reinforce its leading position in the risk assessment and diagnosis of patients in an emergency situation, including those with sepsis and high risk of severe medical complications. To validate TIMP-2 and IGFBP-7 as biomarkers for AKI risk assessment, Astute analyzed the biomarkers in two rigorous company-sponsored, multicenter, observational clinical studies. In these studies, the NephroCheck Test identified the majority of patients manifesting moderate or severe AKI within 12 hours of assessment.

bioMérieux SA to Report Fiscal Year 2014 Results on Jan 22, 2015

bioMérieux SA announced that they will report fiscal year 2014 results Pre-Market on Jan 22, 2015

bioMérieux and Astute Medical, Inc. Signs Global Agreement to Develop and Market Nephrocheck Test for Vidas

bioMérieux and Astute Medical, Inc. announced that they have signed a global, semi-exclusive agreement regarding the development of a test for the early risk assessment of acute kidney injury (AKI). This innovative test, known as the NephroCheck Test, detects the presence of two biomarkers: TIMP-2 (Tissue Inhibitor Metalloproteinases-2) and IGFBP-7 (Insulin-like Growth Factor-Binding Protein-7). AKI is a major public health threat that is common, costly and potentially fatal in hospitalized patients. Through this worldwide agreement, Astute Medical grants bioMérieux a license to develop, produce and market the NephroCheck Test for use on its immunoassay system range VIDAS, miniVIDAS and VIDAS. Up to 50% of severely ill patients develop AKI, which can result in prolonged stays at hospital, especially in intensive care units, thus leading to higher cost of care. The guidelines published by the foundation "Kidney Disease Improving Global Outcomes (KDIGO)" recommend that patients be assessed for risk of AKI to protect their kidney function. Current methods for risk assessment are insufficient, thereby placing substantial numbers of patients at serious risk of complications and death.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIM:FP €96.03 EUR +0.41

BIM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $46.23 USD +0.58
Bio-Rad Laboratories Inc $132.91 USD -0.24
Cepheid $56.35 USD -0.41
QIAGEN NV €22.32 EUR +0.147
Siemens Ltd 1,411 INR -16.90
View Industry Companies
 

Industry Analysis

BIM

Industry Average

Valuation BIM Industry Range
Price/Earnings 22.6x
Price/Sales 1.9x
Price/Book 2.4x
Price/Cash Flow 22.5x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMERIEUX, please visit www.biomerieux.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.